Side-by-side comparison of AI visibility scores, market position, and capabilities
Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.
Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.
Serverless GPU cloud platform for AI/ML with Python-native deployment and per-second billing; developer-favorite scaling from zero competing with Replicate and Beam for AI compute.
Modal is a serverless cloud computing platform purpose-built for AI and machine learning workloads — providing on-demand GPU compute that scales instantly from zero with per-second billing, container management, distributed training support, and a Python-native developer experience that makes running ML workloads in the cloud feel as simple as running code locally. Founded in 2021 in New York City and backed by Redpoint Ventures and other investors, Modal has grown rapidly as AI development has accelerated demand for flexible, developer-friendly GPU infrastructure.\n\nModal's developer experience is its primary differentiator — engineers write Python functions decorated with @modal.function() and deploy them to the cloud with a single command, with Modal handling container building, GPU provisioning, auto-scaling, and execution. The platform supports training jobs that need distributed compute across multiple GPUs, model serving endpoints that scale to zero when unused (eliminating idle GPU costs), and batch inference jobs that process large datasets. The per-second billing model means developers pay only for actual compute time, not provisioned instances.\n\nIn 2025, Modal competes in the AI infrastructure market with Replicate, Beam, Banana, and major cloud providers' managed ML services (AWS SageMaker, Google Vertex AI, Azure ML) for serverless GPU compute. The market for AI-specific cloud infrastructure has grown dramatically as the number of ML engineers deploying models to production has expanded — traditional cloud providers require significant DevOps expertise to use GPU instances effectively, while Modal's Python-native approach reduces the barrier to entry. Modal has attracted a strong developer following among AI researchers and ML engineers building production AI applications. The 2025 strategy focuses on growing the developer community, adding enterprise features (dedicated GPU capacity, private networking, compliance), and expanding the hardware options available (H100 GPUs, custom accelerators).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.